Cardiac hypertrophy is a main contributor to heart failure, where therapeutic options are limited. Increasing evidence exists regarding up-regulation of histone lysine-specific demethylase 4A (KDM4A) in patients with cardiac hypertrophy as a risk factor, although the mechanisms behind are not well understood.